Fatigue in @entity43 XXXX : a neglected issue?

@entity1 @entity43 @entity308 @entity5 @entity1295 @entity148
BACKGROUND: Although @entity1295 is a commonly reported symptom in @entity5 @entity1 it is rarely investigated, especially in @entity1 with @entity43 . The main focus of the current study was to assess @entity1295 in these @entity1 and to investigate the impact of @entity1295 and other clinical and psychosocial variables on their quality of life (QOL). METHODS: Ninety-eight @entity43 survivors (average age of 57.4 +/- 12.5 years) were included in the study. All @entity1 had received @entity5 therapy but had not been treated for at least 6 months. The average time elapsed since first diagnosis was 5.7 +/- 5.5 years. Fatigue was measured with the Multidimensional Fatigue Inventory (MFI-20) and QOL was measured with the Functional Assessment of @entity5 Therapy (FACT)- @entity43 part and the European Organization for Research and Treatment of @entity5 Care Questionnaire, including the @entity43 module. RESULTS: Thirty-two of 98 @entity43 @entity1 (32.7%, 95% confidence interval, 23.5-42.9%) reported MFI-20 General Fatigue scores >/= 12.0 and therefore could be characterized as suffering from @entity1295 . This group of @entity1 had a significantly lower QOL, had higher scores of @entity148 and @entity308 , and perceived that they had less social support. In a multiple regression model, mental adjustment, social support, @entity148 , and @entity308 as well as @entity1295 were significant predictors of QOL (FACT-generic part total score) whereas clinical and sociodemographic variables were not. CONCLUSION: A remarkably high proportion of @entity43 survivors suffered from @entity1295 . Because this symptom is a key predictor of QOL, it should be given more attention in aftercare programs.
